|Dr. J. Mel Sorensen||CEO, Pres & Director||902.25k||N/A||1957|
|Dr. Robert A. Beardsley M.B.A., Ph.D.||Co-Founder & COO||627.52k||N/A||1962|
|Mr. Christopher Degnan||Chief Financial Officer||636.2k||N/A||1980|
|Dr. Dennis P. Riley Ph.D.||Chief Scientific Officer, Emeritus||N/A||N/A||N/A|
|Ms. Jennifer Evans Stacey Esq.||Chief Legal & Compliance Officer and Sec.||N/A||N/A||1965|
|Dr. Jon T. Holmlund M.D.||Chief Medical Officer||N/A||N/A||1957|
|Mr. Mark J. Bachleda M.B.A., Pharm.D.||Chief Commercial Officer||N/A||N/A||1975|
|Ms. Andie Collier||Sr. VP of Regulatory Affairs||N/A||N/A||N/A|
|Ms. Judy Schnyder||Sr. VP of Clinical Operations & Data Management||N/A||N/A||N/A|
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Galera Therapeutics, Inc.’s ISS Governance QualityScore as of May 1, 2022 is 7. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 8; Compensation: 8.